Skip to main content

Table 3 Annual cumulative proportion of patients initiating c-DMARD and b-DMARD

From: Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study

  Persistent oligoarticular JIA (n = 78) Extended oligoarticular JIA (n = 56) Polyarticular JIA RF- (n = 103) Polyarticular JIA RF + (n = 26) ERA (n = 62) Total (n = 325)
Cumulative proportion of patients initiating first c-DMARD, % (95%CI)
1 year 26% (15–35) 48% (33–60) 87% (79–92) 96% (74–99) 66% (52–76) 62% (56–67)
2 years 39% (27–49) 66% (51–76) 97% (91–99) 100% 83% (70–90) 76% (70–80)
3 years 46% (33–57) 72% (57–82) 99% (93–100) 100% 87% (75–93) 80% (74–84)
Cumulative proportion of patients initiating first b-DMARD, % (95%CI)
1 year 2% (0–6) 11% (2–18) 28% (19–36) 42% (20–58) 31% (18–41) 21% (16–25)
2 years 5% (0–10) 25% (13–36) 40% (29–49) 58% (34–73) 38% (24–49) 30% (25–35)
3 years 8% (2–15) 25% (13–36) 53% (42–62) 69% (42–84) 48% (33–60) 38% (32–43)
Median estimated time from index date to the date of first prescription, years (95% CI)b
c-DMARDs 3.5 (2.3-∞) 1.0 (0.61–1.93) 0.1 (0.02–0.26) 0 (0–0.17) 0.4 (0.21–0.90) 0.54 (0.34–0.69)
b-DMARDs NEa 7.11 (4.00-∞) 2.78 (2.04–4.34) 1.58 (0.71-∞) 4.20 (2.43-∞) 5.06 (4.01–7.15)
  1. JIA Juvenile idiopathic arthritis, RF Rheumatoid factor negative, RF Rheumatoid factor positive, ERA Enthesis-related arthritis, c-DMARDs Conventional disease anti-rheumatic drugs, b-DMARDs Biologic disease anti-rheumatic drugs
  2. aNE: not estimated, the median could not be estimated because fewer than 50% of patients had a c-DMARD or b-DMARD prescribed
  3. bEstimates were calculated using Kaplan–Meier analysis to account for censoring